Multisystem Inflammatory Syndrome in Children—United States, February 2020–July 2021
Author(s) -
Allison D. Miller,
Laura D. Zambrano,
Anna R Yousaf,
Joseph Y. Abrams,
Lu Meng,
Michael Wu,
Michael Melgar,
Matthew E. Oster,
Shana E Godfred Cato,
Ermias D. Belay,
Angela P. Campbell,
Gloria E Anyalechi,
Anna Bowen,
Tuyen Do,
Paul A. Gastañaduy,
Katherine Lindsey,
Sancta B. St. Cyr,
Ramandeep Kaur,
Xandy Peterson Pompa,
Chloe E. Le Marchand,
Jason Robert C Singson,
Shan C O’Brien,
Ann Schmitz,
Carola I Torres Díaz,
Walaa M Elbedewy,
Melissa TobinD’Angelo,
Heather D. Reid,
Marielle Fricchione,
Sara Hallyburton,
Gillian Richardson,
Julie Hand,
Dylan Leach,
Cole Burkholder,
Sarah Lim,
Deepam Thomas,
Donna L Gowie,
Elizabeth Dufort,
Ellen H. Lee,
Ayotola Falodun,
Courtney Dewart,
Zachary J Colles,
Jennifer L. Wallace,
LaKita D Johnson,
Kristina L Herring,
Andrea R Liptack
Publication year - 2021
Publication title -
clinical infectious diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.44
H-Index - 336
eISSN - 1537-6591
pISSN - 1058-4838
DOI - 10.1093/cid/ciab1007
Subject(s) - medicine , covid-19 , medline , pediatrics , virology , outbreak , infectious disease (medical specialty) , disease , political science , law
Background Multisystem inflammatory syndrome in children (MIS-C) is a severe hyperinflammatory condition in persons aged <21 years associated with antecedent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Our objective was to describe MIS-C cases reported to Centers for Disease Control and Prevention’s (CDC’s) national surveillance since the coronavirus disease 2019 (COVID-19) pandemic began. Methods We included patients meeting the MIS-C case definition with onset date from 19 February 2020 through 31 July 2021, using CDC’s MIS-C case report form, which collects information on demographics, clinical presentation, and laboratory results. Trends over time across 3 MIS-C pandemic waves were assessed using Cochran-Armitage test for categorical and Jonckheere-Terpstra test for continuous variables. Results Of 4901 reported cases, 4470 met inclusion criteria. Median patient age increased over time (P < .001), with a median of 9 years (interquartile range, 5–13 years) during the most recent (third) wave. Male predominance also increased (62% in third wave, P < .001). A significant (P < .001) increase in severe hematologic and gastrointestinal involvement was observed across the study period. Frequency of several cardiovascular complications (ie, cardiac dysfunction, myocarditis, and shock/vasopressor receipt) and renal failure declined (P < .001). Provision of critical care including mechanical ventilation (P < .001) and extracorporeal membrane oxygenation (ECMO; P = .046) decreased, as did duration of hospitalization and mortality (each P < .001). Conclusions Over the first 3 pandemic waves of MIS-C in the United States, cardiovascular complications and clinical outcomes including length of hospitalization, receipt of ECMO, and death decreased over time. These data serve as a baseline for monitoring future trends associated with SARS-CoV-2 B.1.617.2 (Delta) or other variants and increased COVID-19 vaccination among children.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom